Difference between revisions of "Part:BBa K5083002:Design"

 
 
Line 13: Line 13:
 
===Source===
 
===Source===
  
−
a
+
RCSB(PDBid:5NH3)
  
 
===References===
 
===References===
 +
[1] Morvan F, Rondeau J M, Zou C, et al. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy[J]. Proceedings of the National Academy of Sciences, 2017, 114(47): 12448-12453.
 +
[2] Tsuchida K, Nakatani M, Hitachi K, et al. Activin signaling as an emerging target for therapeutic interventions[J]. Cell Communication and Signaling, 2009, 7: 1-11.

Latest revision as of 02:06, 14 September 2024


Bimagrumab


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

a


Source

RCSB(PDBid:5NH3)

References

[1] Morvan F, Rondeau J M, Zou C, et al. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy[J]. Proceedings of the National Academy of Sciences, 2017, 114(47): 12448-12453. [2] Tsuchida K, Nakatani M, Hitachi K, et al. Activin signaling as an emerging target for therapeutic interventions[J]. Cell Communication and Signaling, 2009, 7: 1-11.